Alexander J. Denner - Apr 2, 2025 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Director, 10%+ Owner
Signature
SARISSA CAPITAL MANAGEMENT LP, By: /s/ Mark DiPaolo, Name: Mark DiPaolo, Title: Senior Partner, General Counsel
Stock symbol
IRWD
Transactions as of
Apr 2, 2025
Transactions value $
$0
Form type
4
Date filed
4/4/2025, 04:05 PM
Previous filing
Mar 17, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Award $0 +10.4K +6.66% $0.00 167K Apr 2, 2025 Direct F1
holding IRWD Class A Common Stock 16.4M Apr 2, 2025 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
F2 Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which SarissaCapital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of theSarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.

Remarks:

Exhibit 24 - Limited Power of Attorney